DXCM financials
DexCom, Inc. · end-of-day data as of Oct 16, 2026
DexCom, Inc.
$86.04+20.3%
Buy · 29 analystsPT $96.98 +12.7%
DXCM reported revenue of $1.31B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 13.1% from a year earlier. It posted diluted EPS of $0.64, free cash flow of $185M and a net margin of 19.0%.
Valuation
- P/E34.0x
- P/E vs own+11.1%
- P/E vs sector+20.8%
- FCF yield+4.3%
- Market cap$32.47B
Quarterly results
Q2 FY2026: Revenue +13.1% year over year, free cash flow 14.1% of revenue, operating margin 24.3%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $1.31B | 0.64 | $185M | 63.4% | 24.3% | 19.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.19B | 0.51 | $449M | 62.9% | 21.4% | 16.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.26B | 0.68 | $192M | 62.9% | 25.6% | 21.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.21B | 0.70 | $579M | 60.5% | 20.1% | 23.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.16B | 0.45 | $209M | 59.5% | 18.4% | 15.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.04B | 0.27 | $96.8M | 56.9% | 12.9% | 10.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.11B | 0.38 | $177M | 58.9% | 17.0% | 13.6% |
| Q3 FY2024 | Sep 30, 2024 | $994M | 0.34 | $88.3M | 59.7% | 15.3% | 13.5% |
| Q2 FY2024 | Jun 30, 2024 | $1B | 0.35 | $213M | 62.4% | 15.7% | 14.3% |
| Q1 FY2024 | Mar 31, 2024 | $921M | 0.36 | $152M | 61.0% | 11.0% | 15.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.03B | 0.62 | $81.1M | 63.5% | 21.0% | 24.8% |
| Q3 FY2023 | Sep 30, 2023 | $975M | 0.29 | $219M | 63.9% | 21.1% | 12.4% |